Rocket Doctor AI

Rocket Doctor AI FCF/Debt

Delisted

The Free Cash Flow to Debt Ratio of Rocket Doctor AI (TRUE.CN) as of Nov 16, 2026 is -2,921.12 %. In the previous year, Free Cash Flow to Debt Ratio was -126.56 % — a change of 2,208.16% (lower).

FCF/Debt

-2,921.12 %

YoY

2,208.16%

Last updated:

Free Cash Flow to Debt Ratio of Rocket Doctor AI is 2024 -2,921.12 % . Free Cash Flow to Debt Ratio of Rocket Doctor AI was 2023 -126.56 % . It decreases by 2,208.16% lower compared to the previous year.

The Rocket Doctor AI FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2022
-257.48 CAD
Jan 1, 2023
-126.56 CAD
Jan 1, 2024
-2,921.12 CAD
The Rocket Doctor AI FCF/Debt history
YEARFCF/DebtYoY
-2,921.12 %+2,208.16%
-126.56 %-50.85%
-257.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rocket Doctor AI Stock analysis

What does Rocket Doctor AI do? Treatment.com AI Inc generates revenue through its Treatment Digital Health App, a symptom assessment tool developed by a global team of doctors and engineers. The app provides predictive health insights using disease rate estimates, geographic variation data, and medical research, targeting patients and caregivers seeking informed health decisions. The company also offers medical education solutions and clinical advisor services, serving healthcare professionals and institutions globally. Revenue streams include subscriptions for app access and tailored medical education programs. The Treatment Digital Health App is designed for widespread use, offering advanced medical knowledge access to users worldwide. Medical clinic solutions are integrated into the platform, supporting healthcare providers in decision-making. Clinical advisor services leverage the AI platform to assist clinics and institutions with specialized medical guidance. These offerings are marketed to healthcare consumers, clinics, and educational institutions as part of the company's global healthcare technology strategy. Treatment.com AI Inc's business model focuses on AI-driven health solutions, with the Treatment Digital Health App as its primary product. The app's predictive health assessments are updated regularly by medical professionals, ensuring relevance and accuracy. The company monetizes through direct consumer subscriptions and B2B partnerships with medical clinics and educational providers, emphasizing global accessibility and evidence-based medical insights. Rocket Doctor AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rocket Doctor AI stock

Free Cash Flow to Debt Ratio of Rocket Doctor AI is -2,921.12 % in 2024.

Free Cash Flow to Debt Ratio of Rocket Doctor AI changed from -126.56 % to -2,921.12 %, representing a 2,208.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Rocket Doctor AI since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Rocket Doctor AI with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Rocket Doctor AI

All Key Metrics — Rocket Doctor AI